Visualizar
Iniciar Como:
|
Datos del Documento
Utilice este identificador para citar o enlazar este documento:
https://ria.asturias.es/RIA/handle/123456789/14366
|
| Título: | Effects of calcitriol and paricalcitol on renal fibrosis in CKD. |
| Autores: | Martinez Arias, Laura
Panizo García, Sara
Alonso Montes, Cristina
Martín Virgala, Julia
Martín Carro, Beatriz
Fernández Villabrille, Sara
García Gil-Albert, Carmen
Palomo Antequera, Carmen
Fernández Martín, José Luis
Ruiz Torres, María Piedad
S. Dusso, Adriana
Carrillo Lopez, Natalia
Cannata Andía, Jorge B.
Naves Diaz, Manuel |
| Palabras Claves: | ckd
renal fibrosis
inflamatory infiltration
epithelial/mesenchymal-transition
VIDRAs |
| Fecha Edición: | 26-Abr-2021 |
| Cita Bibliográfica: | 10.1093/ndt/gfaa373 |
| Resumen: | BACKGROUND: In chronic kidney Disease (CKD) the activation of the
renin-angiotensin-aldosterone system and renal inflammation stimulate renal fibrosis and the
progression to end-stage renal disease. The low levels of vitamin D receptor (VDR) and its activators
(VDRAs) contribute to worsen secondary hyperparathyroidism and renal fibrosis.
METHODS: The 7/8 nephrectomy model of experimental chronic renal failure (CRF) was used to
examine the antifibrotic effects of treatment with two VDRAs (paricalcitol and calcitriol at
equivalent doses (3/1 dose ratio) during 4 weeks.
RESULTS: CRF increased the activation of the renin-angiotensin-aldosterone system, renal
inflammation and interstitial fibrosis. Paricalcitol treatment reduced renal collagen I and renal
interstitial fibrosis by decreasing the activation of the renin-angiotensin-aldosterone system through
renal changes in renin, ATR1 and ATR2 mRNAs levels and renal inflammation by decreasing renal
inflammatory leukocytes (CD45), ADAM17 mRNA, TGF-β mRNA and protein and maintaining
E-cadherin mRNA levels. Calcitriol showed similar trends without significant changes in most of
these biomarkers.
CONCLUSIONS: Paricalcitol effectively attenuated the renal interstitial fibrosis induced by CRF
through a combination of inhibitory actions on the renin-angiotensin-aldosterone system,
inflammation and epithelial/mesenchymal transition. |
| URI: | https://ria.asturias.es/RIA/handle/123456789/14366 |
| Aparece en las Colecciones: | Sanidad
|
Archivos en este documento:
Todos los documentos en RIA están protegidos por derechos de autor.
|
DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard -
Contacto